3692.HK · HKG · Healthcare
Hansoh Pharmaceutical Group Company Limited
Also onConsensus Drift
Implied value per share
HKD 29.89
Market price
HKD 34.30
Implied upside
-12.9%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · CNY model at 1.1708
Current EV/EBITDA of 29.7x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (CNY). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | CNY 17.6bn | CNY 20.6bn | CNY 24.1bn | CNY 28.2bn | CNY 33.0bn | +17.0% |
| EBIT | CNY 5.6bn | CNY 6.6bn | CNY 7.7bn | CNY 9.0bn | CNY 10.5bn | +17.0% |
| NOPAT | CNY 4.9bn | CNY 5.7bn | CNY 6.6bn | CNY 7.8bn | CNY 9.1bn | +17.0% |
| Add depreciation & amortisation | CNY 579.7m | CNY 678.3m | CNY 793.6m | CNY 928.6m | CNY 1.1bn | +17.0% |
| Less capital expenditure | CNY -625.8m | CNY -732.2m | CNY -856.8m | CNY -1.0bn | CNY -1.2bn | +17.0% |
| Less increase in working capital | CNY 911.2m | CNY 1.1bn | CNY 1.2bn | CNY 1.5bn | CNY 1.7bn | -17.0% |
| Free cashflow to firm | CNY 5.7bn | CNY 6.7bn | CNY 7.8bn | CNY 9.2bn | CNY 10.7bn | +17.0% |
| Discount factor | 0.9616 | 0.8891 | 0.8222 | 0.7602 | 0.7029 | - |
| Present value | CNY 5.5bn | CNY 5.9bn | CNY 6.4bn | CNY 7.0bn | CNY 7.5bn | +8.2% |
| Present Value Of The Forecast | CNY 32.4bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 3.20% | HKD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 7.00% | Market assumption |
| Beta | 0.707 | Reported 0.563, pulled toward 1.0 (Blume) |
| Cost of equity | 8.15% | Risk-free + beta x equity risk premium |
| Cost of debt | 3.20% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | CNY 208.0bn | 99.9% of capital |
| Total debt | CNY 105.1m | 0.1% of capital, book value as a proxy |
| Tax rate | 13.5% | Effective, capped at statutory |
| WACC | 8.15% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
73% of EV
- Forecast FCFF, final year
- CNY 10.7bn
- Capex at depreciation, working capital in reinvestment
- CNY 9.1bn
- Less reinvestment at g/ROIC (23.7% of NOPAT)
- CNY -2.2bn
- Capitalised
- CNY 7.0bn
- ROIC (reported)
- 10.6%
- Terminal value, undiscounted
- CNY 126.4bn
- Terminal value, discounted
- CNY 88.8bn
- Enterprise value
- CNY 121.2bn
- Less net debt
- CNY -31.5bn
- Equity value
- CNY 152.7bn
Exit at 20.0x EBITDA
83% of EV
- Terminal value, undiscounted
- CNY 232.0bn
- Terminal value, discounted
- CNY 163.1bn
- Enterprise value
- CNY 195.5bn
- Less net debt
- CNY -31.5bn
- Equity value
- CNY 227.0bn
Spread between methods: 39%.
Sensitivity
Value per share (CNY) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.15% | 32.80 | 34.20 | 35.96 | 38.27 | 41.42 |
| 7.15% | 28.05 | 28.77 | 29.63 | 30.68 | 32.02 |
| 8.15% | 24.72 | 25.10 | 25.53 | 26.03 | 26.64 |
| 9.15% | 22.26 | 22.44 | 22.65 | 22.88 | 23.15 |
| 10.15% | 20.36 | 20.44 | 20.52 | 20.60 | 20.70 |
Outlined: this model. Green text: above today's price of 29.30. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 17.0% | 21.3% | +4.3pp |
| EBIT margin | 31.9% | 38.1% | +6.2pp |
| Discount rate | 8.1% | 7.2% | -0.9pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.